These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 34853164)
1. Prognostic significance of tumour budding, tumour-stroma ratio and desmoplastic stromal reaction in gall bladder carcinoma. Goyal S; Banga P; Meena N; Chauhan G; Sakhuja P; Agarwal AK J Clin Pathol; 2023 May; 76(5):308-314. PubMed ID: 34853164 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of the tumor-stroma ratio in gallbladder cancer. Li H; Yuan SL; Han ZZ; Huang J; Cui L; Jiang CQ; Zhang Y Neoplasma; 2017; 64(4):588-593. PubMed ID: 28485165 [TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of tumour-stroma ratio in endometrial carcinoma. Panayiotou H; Orsi NM; Thygesen HH; Wright AI; Winder M; Hutson R; Cummings M BMC Cancer; 2015 Dec; 15():955. PubMed ID: 26674153 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of desmoplastic stromal reaction, tumor budding and tumor-stroma ratio in stage II colorectal cancer. Fan S; Cui X; Zheng L; Ma W; Zheng S; Wang J; Qi L; Ye Z J Gastrointest Oncol; 2022 Dec; 13(6):2903-2921. PubMed ID: 36636094 [TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of tumour-stroma ratio in early-stage oral tongue cancers. Almangush A; Heikkinen I; Bakhti N; Mäkinen LK; Kauppila JH; Pukkila M; Hagström J; Laranne J; Soini Y; Kowalski LP; Grénman R; Haglund C; Mäkitie AA; Coletta RD; Leivo I; Salo T Histopathology; 2018 Jun; 72(7):1128-1135. PubMed ID: 29427291 [TBL] [Abstract][Full Text] [Related]
6. Impact of tumour stroma-immune interactions on survival prognosis and response to neoadjuvant chemotherapy in bladder cancer. Liu L; Xu L; Wu D; Zhu Y; Li X; Xu C; Chen K; Lin Y; Lao J; Cai P; Li X; Luo Y; Li X; Huang J; Lin T; Zhong W EBioMedicine; 2024 Jun; 104():105152. PubMed ID: 38728838 [TBL] [Abstract][Full Text] [Related]
7. Tumour-stroma ratio outperforms tumour budding as biomarker in colon cancer: a cohort study. Smit MA; van Pelt GW; Terpstra V; Putter H; Tollenaar RAEM; Mesker WE; van Krieken JHJM Int J Colorectal Dis; 2021 Dec; 36(12):2729-2737. PubMed ID: 34533595 [TBL] [Abstract][Full Text] [Related]
8. Prognostication for oral squamous cell carcinoma patients based on the tumour-stroma ratio and tumour budding. Dourado MR; Miwa KYM; Hamada GB; Paranaíba LMR; Sawazaki-Calone Í; Domingueti CB; Ervolino de Oliveira C; Furlan ECB; Longo BC; Almangush A; Salo T; Coletta RD Histopathology; 2020 May; 76(6):906-918. PubMed ID: 31984527 [TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of Tumour Budding and Desmoplastic Reaction in Intestinal-Type Gastric Adenocarcinoma. Pun C; Luu S; Swallow C; Kirsch R; Conner JR Int J Surg Pathol; 2023 Sep; 31(6):957-966. PubMed ID: 35726174 [No Abstract] [Full Text] [Related]
10. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study. Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF Int J Colorectal Dis; 2018 Aug; 33(8):1115-1124. PubMed ID: 29785462 [TBL] [Abstract][Full Text] [Related]
11. Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor-stroma ratio in colon cancer. Polack M; Smit MA; van Pelt GW; Roodvoets AGH; Meershoek-Klein Kranenbarg E; Putter H; Gelderblom H; Crobach ASLP; Terpstra V; Petrushevska G; Gašljević G; Kjær-Frifeldt S; de Cuba EMV; Bulkmans NWJ; Vink GR; Al Dieri R; Tollenaar RAEM; van Krieken JHJM; Mesker WE; ESMO Open; 2024 Apr; 9(4):102988. PubMed ID: 38613913 [TBL] [Abstract][Full Text] [Related]
12. Tumour Budding and Tumour Stroma Ratio are Reliable Predictors for Death and Recurrence in Elderly Stage I Colon Cancer Patients. Zengin M Pathol Res Pract; 2019 Nov; 215(11):152635. PubMed ID: 31564570 [TBL] [Abstract][Full Text] [Related]
13. Histological categorisation of fibrotic cancer stroma in advanced rectal cancer. Ueno H; Jones AM; Wilkinson KH; Jass JR; Talbot IC Gut; 2004 Apr; 53(4):581-6. PubMed ID: 15016755 [TBL] [Abstract][Full Text] [Related]
14. Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis. Wu J; Liang C; Chen M; Su W Oncotarget; 2016 Oct; 7(42):68954-68965. PubMed ID: 27661111 [TBL] [Abstract][Full Text] [Related]
15. A high tumour-stroma ratio (TSR) in colon tumours and its metastatic lymph nodes predicts poor cancer-free survival and chemo resistance. Strous MTA; Faes TKE; Gubbels ALHM; van der Linden RLA; Mesker WE; Bosscha K; Bronkhorst CM; Janssen-Heijnen MLG; Vogelaar FJ; de Bruïne AP Clin Transl Oncol; 2022 Jun; 24(6):1047-1058. PubMed ID: 35064453 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of tumor budding in gallbladder cancer: application of the International Tumor Budding Consensus Conference scoring system. Kim HN; Lee SY; Kim BH; Kim CY; Kim A; Kim H Virchows Arch; 2021 Jun; 478(6):1071-1078. PubMed ID: 33398430 [TBL] [Abstract][Full Text] [Related]
17. Tumour budding and tumour-stroma ratio in hepatocellular carcinoma. Kairaluoma V; Kemi N; Pohjanen VM; Saarnio J; Helminen O Br J Cancer; 2020 Jul; 123(1):38-45. PubMed ID: 32362654 [TBL] [Abstract][Full Text] [Related]
18. Standardized Assessment of the Tumor-Stroma Ratio in Colorectal Cancer: Interobserver Validation and Reproducibility of a Potential Prognostic Factor. Souza da Silva RM; Queiroga EM; Paz AR; Neves FFP; Cunha KS; Dias EP Clin Pathol; 2021; 14():2632010X21989686. PubMed ID: 33634262 [TBL] [Abstract][Full Text] [Related]
19. The tumor-stroma ratio is an independent predictor of survival in patients with 2018 FIGO stage IIIC squamous cell carcinoma of the cervix following primary radical surgery. Zong L; Zhang Q; Kong Y; Yang F; Zhou Y; Yu S; Wu M; Chen J; Zhang Y; Xiang Y Gynecol Oncol; 2020 Mar; 156(3):676-681. PubMed ID: 31882242 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content - a short report. Sandberg TP; Sweere I; van Pelt GW; Putter H; Vermeulen L; Kuppen PJ; Tollenaar RAEM; Mesker WE Cell Oncol (Dordr); 2019 Jun; 42(3):397-403. PubMed ID: 30847807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]